Oxford, UK, January 12th 2015

PharmaVentures has become the latest Partner to join forces with One Nucleus. Both PharmaVentures and One Nucleus are committed to playing an active and supportive role in assisting in the success of the life sciences sector nationally and internationally. 

The One Nucleus mission is to help enable its member companies to be globally competitive. A key element of supporting their members in achieving such competitiveness is enabling access to first class commercial intelligence and corporate advisory services. Such support provides businesses with the best possible opportunity to develop timely and effective strategies for success. PharmaVentures, together with their PharmaTelevision business, will make their services at specially reduced rates to One Nucleus members.

Fintan Walton, CEO of PharmaVentures explained, “We are delighted to be working with One Nucleus in support of their membership. The support we can make available through our corporate advisory services and PharmaTelevision will make the difference to their partnering and development strategies”. 

Harriet Fear, CEO of One Nucleus said, “Our Partner Programme is a bespoke package of support and collaboration between One Nucleus and larger organisations who are central to the success of the sector. We are very excited that PharmaVentures has become a One Nucleus Partner and is involved in a range of our activities including ON Helix - our major Cambridge based translational research conference we host annually, our Life Science Leadership Series and the Ask One Nucleus online Dashboard”. 

About One Nucleus
One Nucleus is an international membership organisation for life science and healthcare companies. We are based in Cambridge with the majority of our members across the Cambridge/London corridor – at the heart of Europe’s largest life science and healthcare cluster. 

Organisation History
Established in 1997, One Nucleus is a not-for-profit membership organisation located in Cambridge. We have over 470 organisations as members, including pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers. 

One Nucleus’ mission is to maximise the global competitiveness of our members.  For our science and technology-based members, that means them being global leaders in the research, development and commercialisation of healthcare innovations that radically improve the quality of people’s lives around the world. For our business and professional services members, it means them delivering exceptional services that significantly enhance the business performance of their clients. 

For further information, contact: 
Tony Jones, Director of Business Development
Email: tony@onenucleus.com 
Tel: +44 (0)1223 896450
Web:  www.onenucleus.com